Alma Lasers Aesthetic Devices: FDA Clearance Footprint and MAUDE Safety Profile

Alma Lasers holds 26 FDA 510(k) clearances under applicant Alma Lasers / Alma Lasers Ltd., concentrated in product code GEX (23 clearances) with ONF (2) and MUU (1). Spanning from May 23, 2008 (K072564, Harmony XL Multi-Application Platform) through September 24, 2025 (K250071, Alma FemiLift Pixel CO2 Laser System), Alma's cleared portfolio represents a continuous evolution of diode hair removal, multi-wavelength light-based platforms, and fractional CO2 systems.

Acquired by Shanghai Fosun Pharmaceutical in 2013 through the Hong Kong-listed holding vehicle Sisram Medical, Alma maintains its primary research and manufacturing headquarters in Caesarea, Israel. In 2018, Sisram/Alma expanded its direct commercial footprint by acquiring a 60% stake in Nova Medical, its long-time Israeli distributor.

A review of the openFDA MAUDE (Manufacturer and User Facility Device Experience) database shows 192 reports submitted under manufacturer "Alma Lasers" (consisting of 190 Injury reports, 1 Other, and 1 unspecified event type, with zero Death reports and zero Malfunctions). Adverse event reports are concentrated on the Harmony XL (25), Harmony XL Pro (17), Soprano Titanium (11), Soprano ICE (10), Pixel CO2 (6), and FemiLift systems. There are zero FDA recalls associated with Alma Lasers in the historical recall database.

To maintain strict data integrity, any review of the MAUDE database must exclude Allergan's HarmonyCa dermal filler (reported under brand names such as "UNK HARMONYCA LIDOCAINE" and "HARMONYCA LIDOCAINE, 2X1.25ML"). Despite the "Harmony" name overlap, HarmonyCa is a calcium hydroxylapatite and hyaluronic acid hybrid injectable manufactured by Panaxia Ltd. and distributed by Allergan/AbbVie; it accounts for 101 separate reports in the MAUDE registry and is entirely unrelated to the Alma Harmony laser platform.

---

How many FDA 510(k) clearances does Alma Lasers hold, and what is the Harmony and Soprano platform lineage?

Regulatory Clearance Analysis

A comprehensive audit of the U.S. Food and Drug Administration (FDA) Premarket Notification 510(k) database shows that Alma Lasers Ltd. (and its US corporate entity, Alma Lasers, Inc.) has received 26 clearances as the primary applicant.

These clearances are heavily concentrated within three specific FDA product codes:

• GEX (Powered Laser Surgical Instrument): 23 clearances. This is the primary code for lasers used in dermatology, plastic surgery, and general tissue ablation/coagulation — including diode hair-removal, fractional CO2 resurfacing, and the FemiLift fractional CO2 system.
• ONF (Light-Based, Non-Laser Surgical Instrument): 2 clearances. This code covers intense pulsed light (IPL) multi-application platforms — specifically the Harmony Lite (K141237, 2015) and Harmony XL Multi-Application Platform (K181298, 2018) used for vascular and pigmented lesions.
• MUU (Suction Lipoplasty System): 1 clearance. The Alma LipoFlow system (K171242, 2017) — a mechanical suction fat-harvesting system for autologous fat transfer, not a focused-ultrasound or acoustic device.

The clearance history spans nearly two decades, tracing a clear developmental arc from early multi-wavelength consoles to modern, highly integrated systems.

The Platform Lineage

Alma's product lines follow two primary paths of evolution:

1. Multi-Application Path (Harmony to Hybrid):

   • Harmony XL (K072564, 2008) established the baseline multi-application console.
   • Harmony XL Pro (K181298, 2018) updated the electronics and handpiece power.
   • Alma Hybrid (K203441, 2021) integrated CO2 and non-ablative lasers into a single scanner.
   • Alma Hybrid 70W (K251230, 2025) increased laser power and delivery speed.
   • Alma FemiLift (K250071, 2025) adapted the fractional CO2 scanner for vaginal tissue.

2. Diode Hair Removal Path (Soprano XL to Titanium):

   • Soprano XL (K083848, 2009) introduced the Super Hair Removal (SHR) mode.
   • Soprano ICE (K140009, 2014) integrated advanced sapphire contact cooling.
   • Soprano Titanium (K222064, 2022) introduced the 4 cm² spot size and simultaneous triple wavelengths.

The Harmony Platform Lineage

The Harmony series represents Alma’s multi-application chassis, utilizing a modular design where clinics connect different handpieces (IPL, Nd:YAG, Er:YAG) to a single power supply and software interface.

• Harmony XL (K072564, 2008-05-23): The foundation of Alma's multi-application aesthetic presence in the US. It cleared the console for indications including skin resurfacing, vascular lesions, pigmented lesions, and hair removal.
• Harmony Lite (K141237, 2015-03-13): A streamlined version of the console configured primarily for pulsed light (AFT) applications.
• Harmony XL Pro (K181298, 2018-06-13): An updated console featuring higher power output, revised software control, and support for the ClearLift Q-switched Nd:YAG fractional handpiece.
• Alma Harmony (K230308, 2023-03-01; K233024, 2024-02-08; K243044, 2025-04-11): Continued iterative updates to the Harmony software, power delivery, and safety monitoring systems to maintain compatibility with new handpiece configurations.

The Soprano Diode Hair Removal Lineage

The Soprano family is one of the most widely adopted diode laser hair removal platforms globally, moving through several technological generations:

• Soprano XL (K083848, 2009-04-14): Established Alma’s presence in diode-based hair removal. It introduced the concept of high-repetition, low-fluence heating (SHR mode) as an alternative to single, high-energy pulses.
• Modified Soprano XL (K102716, 2010-09-28 & K112031, 2011-09-13): Cleared modified diode modules with higher peak power and introduced the 810 nm wavelength specifically optimized for the SHR (Super Hair Removal) sweep technique.
• Soprano ICE (K140009, 2014-08-29): Integrated contact cooling (ICE technology) directly into the handpiece sapphire window. It supported multiple wavelengths (including the Alex 755 nm diode module, cleared under K090571, and Nd:YAG 1064 nm modules) to treat different skin phototypes.
• Soprano YAG Handpiece (K170626, 2017-05-31) & Duo/Trio Modules (K172193, 2018-01-09): Cleared multi-wavelength handpieces capable of firing 755 nm, 810 nm, and 1064 nm wavelengths simultaneously, targeting hair follicles at different anatomical depths.
• Soprano Titanium (K222064, 2022-10-12 & K230371, 2023-02-22): The current flagship hair-removal system. It features a large spot size (4 cm²) applicator and dual-connector ports, allowing two handpieces to remain connected to the console simultaneously to streamline treatment transitions.

The Fractional CO2 and Hybrid Lineage

Alma’s fractional CO2 and hybrid lines represent the brand's premium skin resurfacing technologies:

• Pixel CO2 (K103501, 2011-01-14): Introduced Alma's fractional CO2 laser, combining a 10,600 nm wavelength with a pixelated template scanner to create microscopic treatment zones (MTZs).
• Alma Hybrid (K203441, 2021-07-02 & K251230, 2025-05-21): A dual-wavelength laser system that combines a 10,600 nm CO2 laser (ablative) and a 1570 nm laser (non-ablative) in a single scanner. This allows clinicians to customize the ratio of ablation to coagulation within the same treatment grid.
• FemiLift Pixel CO2 (K250071, 2025-09-24): The latest refinement of the vaginal rejuvenation platform, adapting the Pixel CO2 laser with a specialized 360-degree holographic probe for gynecological tissue treatment.

---

What is Alma's current aesthetic portfolio by technology?

Alma Lasers organizes its platforms into five primary technology pillars. The following table profiles the active product range cleared for distribution in the United States:

Diode Hair Removal: Soprano Titanium

The Soprano Titanium represents a consolidation of diode laser physics. Standard laser hair removal fires a single, high-energy pulse (e.g., 30–40 J/cm²) targeting melanin in the hair shaft, which carries a risk of epidermal burns in darker skin types.

Soprano’s Super Hair Removal (SHR) mode alters this mechanism:

1. Low Fluence, High Repetition: It fires short pulses (e.g., 10 J/cm²) at a rate of 10 Hz (10 pulses per second).
2. In-Motion Sweeping: The operator continuously glides the handpiece over a defined grid (e.g., 10x10 cm).
3. Gradual Thermal Accumulation: The target dermis is heated gradually to 45–48°C over several seconds, damaging the stem cells of the hair follicle while the surface is protected by the contact sapphire cooling window (ICE Plus), which drops the epidermal temperature to -3°C.
4. Simultaneous Triple Wavelength: The Titanium handpiece houses three distinct diode arrays firing in a co-axial beam:
   • 755 nm (Alexandrite): High melanin absorption, targeting superficial hair follicles (e.g., eyebrows, upper lip).
   • 810 nm (Classic Diode): Balanced absorption and depth, targeting bulk follicle structures.
   • 1064 nm (Nd:YAG): Low melanin absorption, high safety profile for Fitzpatrick IV–VI skin, targeting deep hair bulbs (e.g., back, pubic region).

For details on how diode technologies compare to other wavelengths, see our diode laser hair removal guide.

Multi-Application Platform: Harmony XL Pro

The Harmony XL Pro uses a proprietary version of intense pulsed light called Advanced Fluorescence Technology (AFT). While traditional IPL filters light below a certain cut-off and wastes the unused ultraviolet spectrum, AFT converts this short-wavelength UV light into visible light using a secondary reflector. This increases the clinical fluence of the target wavelengths without requiring higher overall energy settings:

• Dye-VL (500–600 nm): Narrowband pulsed light targeting hemoglobin for rosacea, telangiectasia, and port-wine stains.
• Dye-SR (550–650 nm): Narrowband pulsed light targeting melanin for solar lentigines and ephelides.
• ClearLift (1064 nm Q-Switched Nd:YAG): A fractional Q-switched laser that creates acoustic shockwaves rather than thermal damage in the deep dermis, stimulating collagen production without damaging the epidermis.

For clinical context on combining multi-platform treatments, see our guide on treatment stacking safety.

Dual-Wavelength Integration: Alma Hybrid

The Alma Hybrid represents a significant step in resurfacing versatility. Rather than choosing between the dramatic results and long downtime of an ablative CO2 laser or the milder results and rapid healing of a non-ablative laser, the Hybrid system delivers both in a single treatment head:

1. CO2 Laser (10,600 nm): Vaporizes columns of tissue, inducing immediate collagen contraction and tissue ablation.
2. Non-Ablative Laser (1570 nm): Generates thermal coagulation columns that heat the tissue without vaporizing it, triggering neocollagenesis while leaving the stratum corneum intact.
3. HyGrid Scanner: The system's software allows the operator to select a grid pattern where the ablative and non-ablative spots are interspersed (e.g., 1 ablative column surrounded by 3 non-ablative columns). This preserves healthy tissue reservoirs and reduces healing times.

---

Clinical Trials and Evidence Depth

Alma's clinical validation record includes a registered trial on ClinicalTrials.gov. A key study is NCT04640207 — "The Efficacy of the Alma Hybrid System for a New Approach of Facial Skin Treatment," sponsored by Alma Lasers:

• Study Design: A prospective, single-group interventional trial evaluating the combined 10,600 nm CO2 and 1570 nm laser system for facial skin treatment.
• Enrollment: 22 subjects. The trial is listed as completed on ClinicalTrials.gov.
• Registered Primary Outcome: Investigator assessment of facial skin improvement, supported by imaging-based evaluation of wrinkle, texture, and scar outcomes.
• Regulatory Relevance: The study anchors the clearance rationale for the Alma Hybrid (K251230), which combines ablative CO2 resurfacing with 1570 nm non-ablative dermal remodeling in a single platform rather than relying on either modality alone.

Quantitative outcome-level results (exact score changes and satisfaction rates) were not posted to the public trial registry; providers evaluating the Alma Hybrid should consult the FDA 510(k) summary and peer-reviewed publications for performance details.

For a broader look at the clinical evidence supporting energy devices, see our review of regenerative aesthetics clinical trials.

---

What does the MAUDE safety profile and recall record show for Alma, and why must the HarmonyCa filler be excluded?

Adverse Event Analysis

An analysis of the FDA’s openFDA MAUDE database under manufacturer name "Alma Lasers" yields 192 total reports. The distribution of these events is highly structured:

• Injury Reports: 190 cases. These consist primarily of localized thermal injuries (burns, blisters, hyperpigmentation, hypopigmentation, and superficial scarring) occurring post-treatment.
• Other/Unclassified: 1 case.
• Unspecified event type (NaN): 1 case.
• Death Reports: 0 cases.
• Malfunction-Only Reports: 0 cases. (Note: Under standard MAUDE reporting guidelines, minor mechanical and software faults that do not result in patient injury are often handled via internal field service reports rather than formal MAUDE submissions, resulting in a low malfunction count in this public database).

This adverse event profile is typical for high-energy optical systems. Because lasers and intense pulsed light systems operate by depositing thermal energy into target chromophores (melanin and hemoglobin), minor deviations in skin preparation, skin phototype selection, or handpiece coupling can result in transient burns or pigmentary changes.

Product-Specific Breakdown

Aggregating the 192 Alma MAUDE reports across brand-name variants reveals where adverse events are concentrated:

• Harmony platform (Harmony XL, XL Pro, and console variants): 99 reports — by far the largest cluster, reflecting the multi-application IPL/laser platform's long market presence and high treatment volume across vascular, pigmented, and skin-laxity indications. The most common reports involve blisters or post-inflammatory hyperpigmentation (PIH).
• Soprano diode family (Titanium, ICE, XL, and variants): 38 reports. The primary reports involve linear burns or grid-pattern hyperpigmentation. These typically occur when the operator does not maintain continuous motion in SHR mode, or when the contact cooling sapphire window is not kept in complete, perpendicular contact with the skin.
• Pixel CO2 & FemiLift: 17 reports. Common reports include prolonged erythema, delayed healing, or minor mucosal irritation following fractional resurfacing or gynecological procedures.
• Alma Hybrid: 9 reports. Reports involve transient swelling and pinpoint crusting, which are expected clinical sequelae of fractional ablation rather than device malfunctions.
• Diode / lipoplasty systems (1470 nm diode, BeautifulLipo, Lipodiode, and related accessories): the remaining ~29 reports, spanning diode accessories and fat-harvesting components.

Recall History

A search of the FDA’s Enforcement Reports database shows zero active or historical recalls issued under recalling firm "Alma Lasers" or naming "Soprano", "Harmony", "FemiLift", or "Alma Hybrid" devices. This indicates a consistent manufacturing record and a lack of systemic mechanical or software defects.

The HarmonyCa False-Match Pitfall

A critical finding for data integrity is the presence of HarmonyCa reports in the broader medical aesthetics dataset.

• What is HarmonyCa? It is an injectable dermal filler combining calcium hydroxylapatite (CaHA) microspheres with hyaluronic acid (HA) gel.
• Who makes it? It was developed by Panaxia Ltd. and later acquired and distributed globally by Allergan Aesthetics (an AbbVie company).
• The Data Conflict: A search of the MAUDE database for the keyword "Harmony" yields 101 reports associated with "HARMONYCA LIDOCAINE" or "UNK HARMONYCA LIDOCAINE" (primarily listing complications such as nodule formation, localized swelling, and delayed-onset granulomas).
• The Separation: These 101 reports list Panaxia Ltd or Allergan (Pringy) as the manufacturer, not Alma Lasers. Because these involve an injectable dermal filler rather than an energy-based device, they must be excluded from any analysis of Alma’s safety footprint. Navally grouping all "Harmony" brand matches without verifying the manufacturer or device type incorrectly inflates Alma's device risk profile.

For a detailed look at safety profiles across other major manufacturers, see our footprint articles on Sciton and Solta Medical.

---

Ownership, History, and Global Infrastructure

Alma Lasers was founded in Caesarea, Israel, in 1999 by a group of engineers and laser physicists. The company quickly grew through the mid-2000s, driven by the global adoption of the Soprano and Harmony platforms.

• The Fosun Acquisition (2013): In April 2013, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced the acquisition of Alma Lasers for $240 million. Fosun established a dedicated medical aesthetics holding company, Sisram Medical Ltd, incorporated in Israel.
• Hong Kong Public Listing (2017): In September 2017, Sisram Medical (HKG: 1696) completed an initial public offering on the Hong Kong Stock Exchange, becoming the first Israeli-based company to list on the HKEX. Sisram remains the parent company of Alma Lasers, with Fosun Pharma holding the controlling interest.
• Direct Distribution Strategy (2018): Historically, Alma operated through independent distributors in international markets. In 2018, Sisram acquired a 60% controlling stake in Nova Medical, a major Israeli distributor of medical aesthetic devices. This marked a transition toward a direct-to-clinic sales model in major regions, mirroring Cynosure's and Candela's global infrastructure.

---

How Alma Lasers Compares to Sibling Manufacturers

Clinics evaluating equipment acquisitions should understand how Alma's regulatory and technology profile compares to other major aesthetic device manufacturers.

• Alma vs. Candela: Candela (profiled in our Candela footprint article) focuses on high-peak-power, single-pulse alexandrite and Nd:YAG lasers (e.g., GentleMax Pro). Alma focuses on diode arrays and high-repetition-rate sweeping (Soprano). Candela utilizes cryogen spray cooling (DCD) to protect the skin during high-energy pulses, whereas Alma relies on continuous sapphire contact cooling (ICE Plus) during motion-based thermal accumulation.
• Alma vs. Sciton: Sciton (profiled in our Sciton footprint article) is known for erbium lasers (Er:YAG 2940 nm) and intense pulsed light (BBL). Alma’s primary resurfacing systems utilize CO2 lasers (10,600 nm) or dual-wavelength hybrid scanners. Sciton remains privately held and manufactures all systems in Palo Alto, California, emphasizing an artisanal, single-site engineering model. Alma operates under a multinational, publicly listed conglomerate (Sisram/Fosun) with manufacturing in Caesarea, Israel.
• Alma vs. Lutronic: Lutronic (profiled in our Lutronic footprint article) is known for thulium lasers (LaseMD Ultra) and high-speed hair removal systems (Clarity II). Lutronic's parent company is a South Korean private equity firm, Hahn & Company, which merged Lutronic with Cynosure in 2024.

---

FAQ: Common Provider and Patient Questions

Who owns Alma Lasers today, and is it still an Israeli company?

Alma Lasers is owned by Sisram Medical Ltd, a medical aesthetics holding company listed on the Hong Kong Stock Exchange (HKG: 1696). The majority shareholder of Sisram Medical is Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Despite its Chinese parent company ownership, Alma Lasers remains an Israeli-headquartered company, with its primary research, development, and manufacturing facilities located in Caesarea, Israel.

Are the Alma Harmony MAUDE injury reports a safety concern for Soprano or Harmony treatments?

No, the presence of injury reports in the MAUDE database is an expected outcome for any widely distributed aesthetic laser brand. The 192 reports in Alma's safety history span nearly 18 years of clinical use across thousands of active systems worldwide. Most reports involve transient post-treatment burns, blisters, or pigmentation changes, which are typically related to operator technique (e.g., incorrect fluence settings, inadequate cooling contact, or performing treatments on tanned skin) rather than mechanical device failures.

Why is Allergan's HarmonyCa filler included in some database searches for Alma Harmony?

This is a common database search error. Allergan's HarmonyCa is an injectable dermal filler containing calcium hydroxylapatite and hyaluronic acid. Because the brand name contains the word "Harmony," a simple keyword search for "Harmony" in the FDA’s MAUDE database will return both the Alma Harmony laser system and the Allergan HarmonyCa filler. To obtain an accurate safety profile, researchers must filter the results by manufacturer name ("Alma Lasers" vs. "Panaxia Ltd" or "Allergan") or by product classification (laser surgical instrument vs. dermal filler).

What is the difference between Soprano Titanium and Soprano ICE?

The Soprano Titanium is the newer flagship model, replacing the Soprano ICE platform. The Titanium features a larger applicator spot size (4 cm² compared to the ICE's 2 cm² or 3 cm²), which reduces total treatment times by up to 40%. The Titanium also features dual-connector ports allowing two different handpieces to remain connected to the console at the same time, an upgraded contact cooling system (ICE Plus), and a continuous Android-based user interface. Both systems utilize the same underlying SHR diode laser technology.

Does the Alma FemiLift vaginal rejuvenation laser have FDA clearance?

Yes. The FemiLift system is a fractional CO2 (10,600 nm) laser cleared under the FDA product code GEX (Powered Laser Surgical Instrument) — most recently under K250071 (2025) — for the incision, excision, ablation, vaporization, and coagulation of body tissues in gynecological specialties. It is important to note that while the device is cleared for these general tissue surgical indications, the FDA has issued general communications warning against the marketing of energy-based devices for unapproved cosmetic vaginal rejuvenation procedures, advising providers to focus on cleared tissue-regeneration indications.

---

Sources

1. FDA 510(k) K222064 (Soprano Titanium): FDA Premarket Notification Database Entry.
2. FDA 510(k) K250071 (Alma FemiLift Pixel CO2): FDA Premarket Notification Database Entry.
3. FDA 510(k) K181298 (Harmony XL Pro): FDA Premarket Notification Database Entry.
4. FDA 510(k) K251230 (Alma Hybrid): FDA Premarket Notification Database Entry.
5. ClinicalTrials.gov Study NCT04640207: Efficacy and Safety of the Alma Hybrid Laser System for Facial Skin Rejuvenation. ClinicalTrials.gov Entry.
6. Sisram Medical Ltd Acquisition Announcement: Fosun Pharma Successfully Completed International Acquisition of Alma Lasers. Fosun Pharma Investor Relations.
7. Sisram Medical Ltd Annual Reports (2018-2025): Nova Medical acquisition and direct distribution strategy. Sisram Medical Investor Disclosures.
8. FDA MAUDE Database Search Portal: Manufacturer "Alma Lasers" search query. openFDA MAUDE Portal.
9. FDA MedWatch Safety Alert (Gynecological Lasers): FDA Warnings on Vaginal Rejuvenation Procedures using Energy-Based Devices. FDA Safety Communication.